» Articles » PMID: 9649138

Alterations of TP53 in Microdissected Transitional Cell Carcinoma of the Human Urinary Bladder: High Frequency of TP53 Accumulation in the Absence of Detected Mutations is Associated with Poor Prognosis

Overview
Journal Br J Cancer
Specialty Oncology
Date 1998 Jul 2
PMID 9649138
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

We have used microdissection of paraffin-embedded histological sections and polymerase chain reaction (PCR)-based direct DNA sequencing for 54 transitional cell carcinoma (TCC) of the bladder, to examine critically the association between TP53 nuclear accumulation determined by immunohistochemistry and the presence of TP53 mutations, and to examine their relationship to tumour stage and grade, as well as patient survival. There was a significant association between the presence of TP53-positive nuclei (> 10%) and a higher histological stage and grade (P = 0.0115, P = 0.0151 respectively; Fisher's exact). A significant association between TP53 gene mutations and TP53 nuclear reactivity in more than 10% of tumour cell nuclei was also observed (P = 0.0003; Fisher's exact). Mutations were detected in 18/54 (33%) cases together with the wild-type sequence when analysed from bulk frozen samples, with significant clustering of mutations in exons 7 and 8. The microdissection method distinguished more clearly between heterozygous and/or homozygous alterations of the TP53 tumour-suppressor gene, and clearly showed frequent accumulation of TP53 in the absence of mutations. When microdissecting immunonegative regions from the same paraffin sections, three out of ten samples showed the identical mutations detected in the immunopositive regions. There was a significant association between TP53 immunoreactivity in more than 50% of tumour cell nuclei and decreased survival among all patients (P = 0.0325; log-rank test). The patients with TP53 mutations showed a trend for a shorter survival period; however, the association was not statistically significant at the 95% confidence level (P = 0.132; log-rank test). In conclusion, our observations show that accumulation of TP53 occurs frequently in the absence of mutations, and that such accumulation is nevertheless associated with poor survival when it occurs in a high proportion (> 50%) of tumour cell nuclei.

Citing Articles

A framework to select clinically relevant cancer cell lines for investigation by establishing their molecular similarity with primary human cancers.

Dancik G, Ru Y, Owens C, Theodorescu D Cancer Res. 2011; 71(24):7398-409.

PMID: 22012889 PMC: 3242880. DOI: 10.1158/0008-5472.CAN-11-2427.


Clinicopathological features and prognosis assessment of extranodal follicular dendritic cell sarcoma.

Li L, Shi Y, Guo Z, Qiu T, Guo L, Yang H World J Gastroenterol. 2010; 16(20):2504-19.

PMID: 20503450 PMC: 2877180. DOI: 10.3748/wjg.v16.i20.2504.


Establishment and characterization of human bladder cancer cell lines BexBra1, BexBra2, and BexBra4.

Piantino C, Sousa-Canavez J, Srougi V, Salvadori F, Kato R, Ayres P In Vitro Cell Dev Biol Anim. 2009; 46(2):131-9.

PMID: 19915932 DOI: 10.1007/s11626-009-9252-z.


p53 and chemosensitivity in bladder cancer.

Nishiyama H, Watanabe J, Ogawa O Int J Clin Oncol. 2008; 13(4):282-6.

PMID: 18704627 DOI: 10.1007/s10147-008-0815-x.


Prediction of progression in pTa and pT1 bladder carcinomas with p53, p16 and pRb.

Hitchings A, Kumar M, Jordan S, Nargund V, Martin J, Berney D Br J Cancer. 2004; 91(3):552-7.

PMID: 15226775 PMC: 2409830. DOI: 10.1038/sj.bjc.6601954.


References
1.
Lipponen P, Liukkonen T . Reduced expression of retinoblastoma (Rb) gene protein is related to cell proliferation and prognosis in transitional-cell bladder cancer. J Cancer Res Clin Oncol. 1995; 121(1):44-50. DOI: 10.1007/BF01202728. View

2.
Kusser W, Miao X, Glickman B, Friedland J, Rothman N, Hemstreet G . p53 mutations in human bladder cancer. Environ Mol Mutagen. 1994; 24(3):156-60. DOI: 10.1002/em.2850240303. View

3.
Ellison D, Lunec J, Gallagher P, Steart P, Jaros E, Gatter K . Accumulation of wild-type p53 in meningiomas. Neuropathol Appl Neurobiol. 1995; 21(2):136-42. DOI: 10.1111/j.1365-2990.1995.tb01040.x. View

4.
Vet J, Bringuier P, Schaafsma H, Witjes J, Debruyne F, Schalken J . Comparison of P53 protein overexpression with P53 mutation in bladder cancer: clinical and biologic aspects. Lab Invest. 1995; 73(6):837-43. View

5.
Sjogren S, Inganas M, Norberg T, Lindgren A, Nordgren H, Holmberg L . The p53 gene in breast cancer: prognostic value of complementary DNA sequencing versus immunohistochemistry. J Natl Cancer Inst. 1996; 88(3-4):173-82. DOI: 10.1093/jnci/88.3-4.173. View